![[Webinar] The Smarter SOC Blueprint: Learn What to Build, Buy, and Automate](https://theindustryexpert.com/wp-content/uploads/2026/02/soc.jpg)
[Webinar] The Smarter SOC Blueprint: Learn What to Build, Buy, and Automate
Most security teams today are buried under tools. Too many dashboards. Too much noise. Not enough real progress. Every vendor promises “complete coverage” or “AI-powered automation,” but inside most SOCs, teams are still overwhelmed, stretched thin, and unsure which tools are truly pulling their...
Oral bacterium could drive breast cancer growth and spread
Original story from Johns Hopkins Medicine (MD, USA). Study finds Fusobacterium nucleatum can drive DNA damage, tumor growth and metastasis, with heightened effects in cells with BRCA1 gene mutations. Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for...
4 promising drug discovery updates in cancer research – from fungal pharma to tumor-targeting vaccines
This World Cancer Day (4 February 2026), we take a look at some recent drug discovery developments with the potential to transform the oncology pharma landscape. Cancer remains a leading cause of mortality worldwide, with legions of scientists dedicating their research efforts toward the...
Ransomware Without Encryption: Why Pure Exfiltration Attacks Are Surging
With pure exfiltration, businesses don’t realize they’re a victim until it’s too late. Continue reading →
How Banks Can Protect Their Most Valuable Asset: Customers
Security experts share how banks and financial institutions can defend their people, property and customers. Continue reading →
Leveraging ISACA for Your CMMC Career
The Cybersecurity Maturity Model Certification sets the benchmark for how DoW contractors prove cybersecurity readiness. Continue reading →
Novo combination obesity shot meets goal in diabetes trial
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound. Continue reading →
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease. Continue reading →
GSK walks away from pioneering Wave RNA editing drug
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy. Continue reading →